Second biosimilar G-CSF filed for approval in Japan
This article was originally published in Scrip
Executive Summary
An approval submission has been made in Japan for the manufacture and marketing of a biosimilar version of filgrastim, marking the second filing in recent months for a biosimilar granulocyte colony-stimulating factor (G-CSF) product.